For investors seeking momentum, Invesco S&P SmallCap Health Care ETF (PSCH - Free Report) is probably on radar. The fund just hit a 52-week high, and is up about 77% from its 52-week low price of $83.54/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
PSCH in Focus
This fund targets the small-cap segment of the broad healthcare space. It offers exposure to companies engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies. The fund charges investors 29 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The broad healthcare sector has been an area to watch lately given the excitement over signs of a first successful late-stage COVID-19 vaccine trial. Pfizer (PFE) in collaboration with German drugmaker BioNTech SE announced that their vaccine candidate was more than 90% effective in preventing COVID-19 based on initial data from a large study.
More Gains Ahead?
Currently, PSCH has a Zacks ETF Rank #3 (Hold) with a Medium risk outlook. Therefore, it is hard to get a handle on its future returns one way or the other. However, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For investors seeking momentum, Invesco S&P SmallCap Health Care ETF (PSCH - Free Report) is probably on radar. The fund just hit a 52-week high, and is up about 77% from its 52-week low price of $83.54/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
PSCH in Focus
This fund targets the small-cap segment of the broad healthcare space. It offers exposure to companies engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies. The fund charges investors 29 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The broad healthcare sector has been an area to watch lately given the excitement over signs of a first successful late-stage COVID-19 vaccine trial. Pfizer (PFE) in collaboration with German drugmaker BioNTech SE announced that their vaccine candidate was more than 90% effective in preventing COVID-19 based on initial data from a large study.
More Gains Ahead?
Currently, PSCH has a Zacks ETF Rank #3 (Hold) with a Medium risk outlook. Therefore, it is hard to get a handle on its future returns one way or the other. However, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PSCH - FREE